Name: Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 2 comparison snapshot
Creator: Fliar BI Prism

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1ARQT · Nasdaq

Arcutis

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2016Westlake Village, California$3.01B market cap

View full Companies Radar profile

58Moderate

Snapshot price$23.97as of page date

Monthly-close return+0.3%five-year window

FY2025 revenue$0.37BArcutis Biotherapeutics, Inc.

Net margin-4.3%FY2025

P/E snapshot109.0xone ratio, not a verdict

Prism attention7.9%share across these five

Filing track recordRevenue, USD billions

+9994.2%

FY2022–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 365.6%

52-week position53% through range

$15.13$31.77

News mentions885

Community mentions31partial coverage

U.S.-scope patents249

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal86/100
Management stability90/100
Market position28/100
Capital-event signal51/100
Innovation pulse8/100

Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2AXSM · Nasdaq

Axsome Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2012New York City, New York$10.40B market cap

View full Companies Radar profile

58Moderate

Snapshot price$198.5as of page date

Monthly-close return+502.3%five-year window

FY2025 revenue$0.64BAxsome Therapeutics, Inc.

Net margin-28.7%FY2025

P/E snapshot39.4xone ratio, not a verdict

Prism attention13.3%share across these five

Filing track recordRevenue, USD billions

+1176.0%

FY2022–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 133.7%

52-week position58% through range

$112.9$260.2

News mentions1.5K

Community mentions0partial coverage

U.S.-scope patents687

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal76/100
Management stability90/100
Market position13/100
Capital-event signal71/100
Innovation pulse22/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 2 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3CYTK · Nasdaq

Cytokinetics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1997San Francisco, California$9.86B market cap

View full Companies Radar profile

58Moderate

Snapshot price$70.91as of page date

Monthly-close return+98.4%five-year window

FY2025 revenue$0.09BCYTOKINETICS INC

Net margin-891.6%FY2025

P/E snapshot-15.9xone ratio, not a verdict

Prism attention18.4%share across these five

Filing track recordRevenue, USD billions

+25.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 5.7%

52-week position60% through range

$44.91$88.31

News mentions2.1K

Community mentions24partial coverage

U.S.-scope patents1376

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal87/100
Management stability90/100
Market position10/100
Capital-event signal81/100
Innovation pulse3/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 2 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4ORGO · Nasdaq

Organogenesis

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1985WILMINGTON$221.3M market cap

View full Companies Radar profile

58Moderate

Snapshot price$1.72as of page date

Monthly-close return-87.9%five-year window

FY2025 revenue$0.56BOrganogenesis Holdings Inc.

Net margin6.6%FY2025

P/E snapshot-5.5xone ratio, not a verdict

Prism attention15.4%share across these five

Filing track recordRevenue, USD billions

+20.5%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 4.8%

52-week position3% through range

$1.54$7.08

News mentions1.7K

Community mentions0partial coverage

U.S.-scope patents208

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal83/100
Management stability90/100
Market position15/100
Capital-event signal79/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 3 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5ONC · Nasdaq

BeiGene

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2010Cambridge$40.68B market cap

View full Companies Radar profile

57Moderate

Snapshot price$359.6as of page date

Monthly-close return-0.9%five-year window

FY2025 revenue$5.34BBeOne Medicines Ltd.

Net margin5.4%FY2025

P/E snapshot64.6xone ratio, not a verdict

Prism attention45.0%share across these five

Filing track recordRevenue, USD billions

+1629.8%

FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 103.9%

52-week position80% through range

$253.9$385.2

News mentions5.0K

Community mentions58partial coverage

U.S.-scope patents56

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal79/100
Management stability90/100
Market position13/100
Capital-event signal74/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 2 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Axsome Therapeutics

+502.3%

Cytokinetics

+98.4%

Arcutis

+0.3%

BeiGene

-0.9%

Organogenesis

-87.9%

Latest revenue

USD billions, official filing scope shown on each company card.

BeiGene

$5.34B

Axsome Therapeutics

$0.64B

Organogenesis

$0.56B

Arcutis

$0.37B

Cytokinetics

$0.09B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Organogenesis

6.6%

BeiGene

5.4%

Arcutis

-4.3%

Axsome Therapeutics

-28.7%

Cytokinetics

-891.6%

Prism news attention

Normalized share across these five names; attention is not quality.

BeiGene

45.0%

Cytokinetics

18.4%

Organogenesis

15.4%

Axsome Therapeutics

13.3%

Arcutis

7.9%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

BeiGene leads the conversation

It holds 45.0% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $5.34B.

Price path

Axsome Therapeutics leads the available price paths

Its monthly-close return is +502.3% for the five-year window. At the other end, Organogenesis is -87.9% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Organogenesis has the widest latest margin

Its FY2025 net margin is 6.6%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Cytokinetics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -15.9x while its five-year window price return is +98.4%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · ARQT

Arcutis

885available Prism news records

Prism top themes

Price action & investor response

58

Capital allocation & transactions

32

Legal, arbitration & regulatory

26

Leadership & governance

22

Earnings & financial performance

6

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+3.2%191 latest 12m vs 185 prior 12m

Machine-classified coverage tone

88.1% positive-5.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

atopic dermatitis 19cream dosing accuracy 16seborrheic dermatitis 9stock performance 8eczema 8infantile eczema 8eczema flare 7seborrheic eczema 6

Keyword tag occurrences in available Prism news records.

Coverage: 2010-05-03–2026-06-15 · trend and themes shown through 2026-06

Areas of research · AXSM

Axsome Therapeutics

1,480available Prism news records

Prism top themes

Price action & investor response

96

Capital allocation & transactions

45

Legal, arbitration & regulatory

41

Earnings & financial performance

31

Leadership & governance

9

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+28.8%362 latest 12m vs 281 prior 12m

Machine-classified coverage tone

89.5% positive-0.3 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

ssri effectiveness trials 42treatment-resistant depression studies 32antidepressant response rates 29depression treatment outcomes 20mood stabilizer toxicity 19stock price 17antipsychotic metabolic effects 17share price 14

Keyword tag occurrences in available Prism news records.

Coverage: 2015-03-05–2026-06-19 · trend and themes shown through 2026-06

Areas of research · CYTK

Cytokinetics

2,053available Prism news records

Prism top themes

Price action & investor response

94

Capital allocation & transactions

54

Legal, arbitration & regulatory

43

Leadership & governance

29

Earnings & financial performance

17

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+3.4%366 latest 12m vs 354 prior 12m

Machine-classified coverage tone

77.2% positive-11.4 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

heart failure medications 38hypertrophic cardiomyopathy 33arrhythmogenic rv cardiomyopathy 29iron overload cardiomyopathy 28dilated cardiomyopathy 27stock performance 25treasury shares 24cardiac resynchronization therapy 13

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-19 · trend and themes shown through 2026-06

Areas of research · ORGO

Organogenesis

1,721available Prism news records

Prism top themes

Earnings & financial performance

28

Leadership & governance

13

Price action & investor response

13

Capital allocation & transactions

9

Legal, arbitration & regulatory

4

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-32.1%186 latest 12m vs 274 prior 12m

Machine-classified coverage tone

95.8% positive+1.6 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stem cell banking 12stem cell transplantation 11startup valuation 10tissue regeneration 9cell-based therapies 8biosimilar market entry 8pluripotent stem cells 8net income 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-02 · trend and themes shown through 2026-06

Areas of research · ONC

BeiGene

5,010available Prism news records

Prism top themes

Legal, arbitration & regulatory

116

Earnings & financial performance

89

Price action & investor response

68

Capital allocation & transactions

41

Leadership & governance

37

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-34.7%588 latest 12m vs 900 prior 12m

Machine-classified coverage tone

94.5% positive+3.1 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

angiogenesis inhibitors 75cancer biomarkers 52checkpoint inhibitors lymphoma 44adc therapeutics 30antibody-drug conjugates lymphoma 30stock performance 25t-cell lymphoma 23burkitt lymphoma 22

Keyword tag occurrences in available Prism news records.

Coverage: 2010-10-28–2026-07-16 · trend and themes shown through 2026-07

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

ARQT

Arcutis

31 mentions

Products, pricing and logistics

11

Stock and valuation

4

Workplace and hiring

1

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 31 records remained after filtering.

ONC

BeiGene

58 mentions

Stock and valuation

19

Products, pricing and logistics

11

Workplace and hiring

2

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 58 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

ARQT

Arcutis

through 2026-03-06

Earnings releases 15Leadership changes 7Business contracts 2Company announcements 2Listing / IPO 1

2026-03-06
Earnings releases
Chief Executive Officer Frank Watanabe said the company delivered a “very strong” fourth quarter and full-year 2025, pointing to $127.5 million in fourth-quarter net revenue and $372 million for the year.
2026-03-05
Leadership changes
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
2026-01-29
Business contracts
Arcutis Biotherapeutics, Inc. has mutually terminated its United States promotion agreement with Kowa Pharmaceuticals America, Inc., ending Kowa’s role in promoting ZORYVE roflumilast to primary care physicians and pediatricians.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

AXSM

Axsome Therapeutics

through 2026-03-11

Earnings releases 24Company announcements 4M&A 3Lawsuits 2Listing / IPO 2

2026-03-11
Company announcements
The company plans to double its sales team from 300 to 600 employees by the second quarter of 2026.
2026-02-05
Earnings releases
When Axsome posted its most recent earnings numbers in November, the company demonstrated some impressive growth with its revenue rising by 63% on a year-over-year basis, totaling $171 million (for the period ended Sept. 30, 2025). It also trimmed its net loss from $64.6 million in the prior-year period to $47.2 million.
2025-11-14
M&A
In November 2025, Avenue Therapeutics, Inc. (“Avenue”) announced the acquisition of its subsidiary Baergic by Axsome.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CYTK

Cytokinetics

through 2026-02-03

Earnings releases 11Company announcements 5Listing / IPO 5Leadership changes 3M&A 2

2026-02-03
Earnings releases
Based on Cytokinetics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.94 million and a GAAP net loss of $306.18 million.
2026-01-20
Company announcements
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 15, 2026 it granted stock options to purchase an aggregate of 29,416 shares of common stock and 19,825 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 8 employees.
2025-11-10
Lawsuits
A shareholder class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ORGO

Organogenesis

through 2026-02-26

Earnings releases 29Leadership changes 5Asset acquisitions 1Business contracts 1Lawsuits 1

2026-02-26
Earnings releases
Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million for the fourth quarter of 2025, an increase of $98.4 million compared to net product revenue of $126.7 million for the fourth quarter of 2024.
2025-02-14
Regulatory
Organogenesis Inc., of Canton, Mass., said its bi-layered skin substitute, Apligraf, is included in the Outpatient Prospective Payment System, qualifying the treatment for reimbursement by Medicare when applied in a hospital outpatient setting. The OPPS list, a new program implemented by the Health Care Financing Administration, will take effect on Aug. 1.
2025-02-14
Leadership changes
Royce succeedsThomas Tully, who resigned.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ONC

BeiGene

through 2025-12-31

Company announcements 14Earnings releases 12Leadership changes 7Business contracts 3Lawsuits 3

2025-12-31
Asset acquisitions
The company has entered into a purchase agreement to acquire an approximately 42-acre site with over one million square feet of developable real estate.
2025-02-27
Earnings releases
Total revenue $ 1,127,824 $ 634,409 78 % $ 3,810,241 $ 2,458,779 55 %
2025-02-14
Listing / IPO
some outliers have tipped the scales, with Beigene's $800 million follow-on leading the way.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 6–13. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Arcutis leads the readiness ranking

Its Prism readiness score is 58/100, the highest in this five-company comparison.

Open Arcutis in Companies Radar

Scale and margin leadership sit with BeiGene and Organogenesis

BeiGene has the largest displayed latest revenue at $5.34B; Organogenesis has the widest displayed latest margin at 6.6%.

Open BeiGene in Companies Radar Open Organogenesis in Companies Radar

Comparisons

Strongest versus weakest available price path

Axsome Therapeutics is +502.3% for its five-year window; Organogenesis is -87.9% for its five-year window.

Open Axsome Therapeutics in Companies Radar Open Organogenesis in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $5.34B for BeiGene to $0.09B for Cytokinetics. Entity and filing-period labels remain visible on the company cards.

Open BeiGene in Companies Radar Open Cytokinetics in Companies Radar

Anomalies

BeiGene has the widest attention-readiness rank gap

It ranks #1 by measured news attention (45.0%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open BeiGene in Companies Radar

BeiGene shows a price-operating divergence to inspect

Its displayed filing-revenue change is +1629.8% while its available monthly-close return is -0.9%. The signs differ, but the two measures cover different windows and do not establish causality.

Open BeiGene in Companies Radar

Explanations

Attention measures coverage volume, not quality

BeiGene's 45.0% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open BeiGene in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Arcutis's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 58/100 score.

Open Arcutis in Companies Radar

Stress-test the largest divergence before forming a view

Compare BeiGene's profile with Axsome Therapeutics's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open BeiGene in Companies Radar Open Axsome Therapeutics in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.